• FIITJEE BAHRAIN CENTRE
New diabetic drug to come to UAE

New diabetic drug to come to UAE

NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.

Vildagliptin is an oral anti-diabetic agent that delivers consistent and robust blood sugar control in patients with type 2 diabetes. It is a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, which do not cause weight gain and have low risks for hypoglycaemia. 

The overall market for oral hypoglycaemic agents (OHA) in UAE is estimated to be USD 115 million and DPP-IV inhibitors command nearly 50% share of this market. A novel product, Vildagliptin is available both as monotherapy as well as in combination with metformin. Together Vildagliptin and Vildagliptin + Metformin commands over 30% of the DPP-IV market in UAE.

NeoBiocon has received approvals from the Ministry of Health-UAE for marketing Jalra and Jalra-M in the country and the launch is scheduled for Jan 2016.  These products will be manufactured by Novartis in Europe and marketed and distributed by NeoBiocon in UAE after local release through Neopharma.

Talking about the partnership, Dr. B. R. Shetty, Chairman, Neopharma, said: “We are delighted to extend our partnership with Novartis and Biocon for these novel products. Biocon’s leadership in the diabetes segment will augur well for marketing these brands in UAE.”

Commenting on the development, Dr Kiran Mazumdar-Shaw, CMD, Biocon, said: “Biocon is committed to offer advanced therapies for diabetics the world over. We are indeed pleased to partner with Novartis to offer Jalra and Jalra-M to address the growing needs of type 2 diabetes patients in UAE.”

The partnership between NeoBiocon and Novartis will benefit the large and increasing number of diabetics in the UAE.  This will result in enhancing access to this novel oral hypoglycaemic agent by leveraging the huge marketing network of NeoBiocon & distribution network of NMC Healthcare.  Novartis will continue to market its brands Galvus & Galvusmet in the UAE.

NeoBiocon is amongst the fastest growing pharmaceutical companies in UAE and is ranked amongst the top 25 pharma companies in the region. It is the no.1 generic pharma company in UAE, in the cardiovascular segment with successful brands like Statix (atorvastatin). NeoBiocon is committed to bring innovative products to the GCC market and enhancing capabilities of the local manufacturers. 

Established in 2011, NeoBiocon markets its own brands in UAE & other GCC markets in various therapies such as metabolics, oncology, asthma & allergic rhinitis, anti-infectives and others. Through this partnership with a multinational pharma company, NeoBiocon has further strengthened its resolve to create a positive impact in the lives of the patient’s through innovative products.





Kim and Kanye West expecting fourth child

Kim and Kanye West expecting fourth child

Kim Kardashian has confirmed she is expecting her fourth child with husband Kanye West during a US TV interview. Kim revealed the couple were expecting a boy via a surrogate mother. She was joined by her sisters Kourtney and Khloe Kard

German growth slows

German growth slows

Growth in the German economy fell to 1.5 per cent in 2018, official data showed yesterday, representing a marked slowdown from the previous year’s figure. Officials from federal statistics authority Destatis told a Berlin press c

EU wants end veto on tax

EU wants end veto on tax

The European Commission yesterday proposed to end the veto power member states have over EU tax matters, an idea rejected by several smaller countries including low-tax hub Ireland. A more harmonised tax policy across Europe has long b

Where are the sedans?

Where are the sedans?

A persistent question shadowed all of the shiny new vehicles and highly-produced, glitzy debuts at the Detroit auto show this week: Where are the sedans? Volkswagen was among the few to trumpet a new sedan -- those compact and mid-size